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Abstract
Background: To compare the patients’ and physician’s global assessment of disease activity in Behçet’s syndrome
(BS) and investigate the frequency, magnitude, and determinants of potential discordance.
Methods: A total of 226 adult BS patients with a median (IQR) age of 46.9 (35.6–55.2) years were enrolled across
Italy, Greece, Portugal, and Spain. Demographic, clinical, and therapeutic variables, as well as the patient reported
outcomes, were collected at the recruitment visit. The physical (PCS) and mental (MCS) component summary scores
of the Short Form Questionnaire 36 (SF-36) and the Behçet’s syndrome Overall Damage Index (BODI) were calculated.
Disease activity was assessed by the patients’ (PtGA) and physician’s global assessment (PGA) in a 10-cm visual analog
scale, as well as the Behçet Disease Current Activity Form (BDCAF). Discordance (Δ) was calculated by subtracting the
PGA from the PtGA and defined as positive (PtGA>PGA) and negative (PtGA<PGA) discordance using both a more
stringent (Δ = ±2) and a less stringent (Δ = ±1) cutoff. Univariate and multivariate logistic regressions were performed.
Results: Median PtGA and PGA scores were 2.0 (0.3–5.0) and 1.0 (0.0–3.0) cm, respectively. The discordance prevalence
varied (from 29.6 to 55.3%) according to the cutoff applied, and the majority (> 80%) of disagreements were due to
patients rating higher their disease activity. Higher values of BDCAF were associated to increased rate of positive
discordance. When BDCAF = 0, the median (IQR) values of PtGA and PGA were 0.2 (0–2) and 0 (0–1), respectively. PCS
(adjusted odds ratio (adjOR) 0.96 per unit, 95% CI 0.93–0.98, p = 0.006) and MCS (adjOR 0.96 per unit, 95% CI 0.93–0.99,
p = 0.003) were independently associated with positive discordance using both cutoffs. Active ocular involvement
emerged as a potential determinant of negative discordance (adjOR 5.88, 95% CI 1.48–23.30, p = 0.012).
(Continued on next page)
© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: matteopiga@unica.it
2Dipartimento di Scienze Mediche e Sanità Pubblica, Università di Cagliari, SS
554, 09042 Monserrato, Cagliari, Italy
Full list of author information is available at the end of the article
Floris et al. Arthritis Research & Therapy          (2020) 22:278 
https://doi.org/10.1186/s13075-020-02362-1
(Continued from previous page)
Conclusions: PtGA and PGA should be considered as complementary measures in BS, as patients and physicians may
be influenced by different factors when assessing active disease manifestations. Particularly, PtGA may be a useful tool
in the assessment of BS disease activity, as it carries a low risk to misclassify an inactive disease, and may allow to
capture aspects of the patient’s health that negatively affect his well-being and the treatment.
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Introduction
Behçet’s syndrome (BS) is a multisystem inflammatory
disease of unknown etiology, characterized by strong gen-
etic background, distinctive geographic distribution, and a
wide variability in clinical presentation [1–3]. It typically
manifests with oral and genital ulcers, skin lesions, and
uveitis, but musculoskeletal, nervous, vascular, and gastro-
intestinal involvement may occur leading to significant
morbidity and mortality [4].
Because of its clinical variability, it is difficult to de-
fine the disease activity in BS, and a validated and
widely accepted tool for its measurement is not yet
available.
The patient’s global assessment (PtGA) and physician’s
global assessment (PGA) of disease activity on visual
analogic scales have been frequently used in studies in-
volving patients with BS. Indeed, although not formally
validated, both PtGA and PGA have been endorsed for
inclusion into the OMERACT core set of outcome mea-
sures for BS [5].
According to the European League Against Rheuma-
tism (EULAR) recommendations, the treatment of BS
should be individually tailored and therapeutic decisions
should be based on a consultation between patient and
physician through shared decision-making [6]. Indeed,
many studies on several chronic illnesses have shown
that, when there is concordance between patients’ and
physicians’ judgment on the disease status, adherence to
treatment and outcomes significantly improve [7–9].
However, the patients’ opinions on disease activity
do not always match those of their physicians and
frequent discordance has been demonstrated in sev-
eral rheumatic diseases including rheumatoid arthritis
[10–12], psoriatic arthritis [13, 14], ankylosing spon-
dylitis [15], and systemic lupus erythematosus [16].
Despite its potential clinical relevance, little is known
so far about the frequency, magnitude, and potential
determinants of discordance between patients and
physicians in BS.
In the view of an enhanced patient-physician partner-
ship in the disease management, this study aimed to in-
vestigate the frequency, magnitude, and determinants of
discordance in the patients’ and physician’s global as-




A post hoc analysis on data from patients recruited in
the BODI Project validation cohort was performed. The
BODI Project is an international multicenter cross-
sectional study aiming to develop and preliminarily
validate the Behçet’s syndrome Overall Damage Index
(BODI), a tool specifically designed to identify and meas-
ure organ damage in BS [17]. The BODI validation co-
hort consisted of 228 adult patients (≥ 18 years old),
diagnosed with BS according to the ISG [18] or ICBD
[19] criteria, and having a disease duration of at least 12
months. The study was conducted according to general
and local regulation and approved by the ethics commit-
tee of the coordinating center at the AOU of Cagliari
(Prot. PG/2018/17158).
Data collection
Demographic, clinical, and therapeutic data were assessed
and recorded by the recruiting physician at the enrolment
visit. Self-reported outcomes were recorded by the pa-
tients during the same visit. Active disease manifestations
were categorized as follows: mucocutaneus (oral aphthosis
and/or genital ulcers and/or skin lesions), arthritis, ocular,
and major organ involvement (vascular and/or GI and/or
nervous lesions). The presence of any chronic comorbidity
was also recorded (malignancy, cardiovascular and re-
spiratory disease, metabolic disorders, major depressive
disorder, other immunomediate diseases). Disease activity
was evaluated by the PtGA and PGA, as well as the Behçet
Disease Current Activity Form (BDCAF) [20]. PtGA and
PGA were assessed through a single question (“How active
was your/the patient’s BS during the last week?”) on an
anchored 10-cm visual analogic (0.5-cm graded), where 0
corresponded to “no disease activity” and 10 to “the high-
est disease activity.” At each center, the PGA assessor was
a single physician with expertise in BS. Irreversible organ
damage accrual was also assessed by using the BODI [17].
Different aspects of the health-related quality of life (HR-
QoL) were assessed through the patient-rated Short Form
Questionnaire in 36 items (SF-36), and the physical (PCS)
and mental (MCS) component summary scores were
recorded [21]. Finally, the ongoing therapies at the enrol-
ment visit were recorded.
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Definition of discordance
A discrepancy score was calculated by subtracting the
PGA from the PtGA (“PtGA − PGA”). As there was not
a validated definition of clinically relevant difference be-
tween such measures, two cutoffs, one more stringent
(± 2) and one less stringent (± 1), were chosen by round-
ing to the standard deviation of the mean absolute
discrepancy score in the BODI cohort. Thus, the rela-
tionship between PtGA and PGA was classified in three
categories: (a) positive discordance, when the patient
rated higher than her/his physician (“PtGA − PGA” ≥ + 2
or + 1); (b) negative discordance, when the patient rated
lower than her/his physician (“PtGA − PGA” ≤ − 2 or −
1); and (c) concordance, when the discrepancy score was
> − 2 and < + 2 or > − 1 and < + 1 (Fig. 1).
To assess the potential impact of the extent of disease
activity, when assessed by an objective instrument, the
rate of discordance/concordance was assessed by strati-
fying patients according to different ranges of the cor-
rected BDCAF score (0, 1–3, 4–6, and ≥ 7 points).
Candidate determinants of discordance
Age, gender, disease duration, chronic comorbidities, ac-
tive disease manifestations, and ongoing treatments were
explored as potential demographic, clinical, and thera-
peutic determinants of discordance between PtGA and
PGA. To investigate the potential misleading impact of
damage accrual in the overall assessment of disease ac-
tivity, correlation between BODI score and the PtGA-
PGA discordance was also analyzed. To explore the po-
tential influence of different aspects of the patient’s
mental and physical domains of the HR-QoL, the PCS
and MCS scales of the SF-36 were analyzed as potential
determinants of discrepancy.
Statistical analysis
The sample distribution of variables was described as
mean ± standard deviation (SD) or median with inter-
quartile range (IQR), for continuous variables, or as fre-
quencies and percentages, for categorical variables.
The discrepancy score was calculated, and the preva-
lence of positive and negative discordance was separately
evaluated by using both the thresholds of ± 2 and ± 1.
The association between PtGA-PGA discordance
(dependent variable) and its potential determinants (in-
dependent variables) was evaluated through univariate
and multivariate logistic regression, and results were
presented as odds ratio (OR) with 95% CI both crude
and adjusted (adj). Variables showing associations with
p values ≤ 0.10 in univariate analysis were included in
multivariate analysis. Both for positive and negative dis-
cordance, two separate analyses have been performed
by using the cutoff of ± 2 and ± 1 for significant
discrepancy.
The statistical significance was set for p < 0.05. Statis-
tical analyses were performed using SPSS® software (ver-
sion 24.0, Armonk, NY, USA).
Results
Patients
Out of the 228 patients enrolled in the BODI cohort,
226 were recruited for the present study. Two were ex-
cluded for missing PtGA or PGA data. Males were 111
(49.1%). The median (IQR) enrollment age and disease
Fig. 1 Categorization of PtGA-PGA discordance using a cutoff of (a) ± 2 and (b) ± 1. PtGA, patient global assessment of disease activity; PGA,
physician global assessment of disease activity
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duration were 46.9 (35.6–55.2) and 11.7 (5.9–20.8) years,
respectively. The median (IQR) BDCAF score was 3.0
(0.0–5.0), with 106 (46.9%) patients having at least one
active disease manifestation. Details on the baseline
characteristic of the studied cohort are reported in
Table 1.
Prevalence and magnitude of discordance
In the whole cohort, the median (IQR) PtGA and PGA
scores were respectively 2.0 (0.3–5.0) and 1.0 (0.0–3.0)
cm, with a mean (± SD) absolute discrepancy score of
1.3 (1.5).
When the discordance between PtGA and PGA was
analyzed by using a discrepancy score threshold of ± 2,
positive and negative discordance were recorded in 59
(26.1%) and 8 (3.5%) patients, respectively, whereas con-
cordance was observed in the remaining 159 (70.4%)
cases (Fig. 2a). When a discrepancy score of ± 1 was ap-
plied, positive discordance, negative discordance, and
concordance rates were 101 (44.7%), 24 (10.6%), and 101
(44.7%) patients, respectively (Fig. 2b).
When patients were stratified according to the BDCAF
score, a progressive decrease in the frequency of con-
cordance and a concomitant increase in the frequency of
positive discordance were recorded, both using the cut-
off of ± 2 and, more remarkably, of ± 1. Negative dis-
cordance rate remained substantially stable (Fig. 3). In
patients with BDCAF = 0, the median (IQR) value of
PtGA and PGA was 0.2 (0–2) and 0 (0–1), respectively.
Determinants of positive discordance (PtGA>PGA)
In univariate analysis, positive discordance, as defined by
a discrepancy score ≥ + 2, was significantly associated
with ongoing treatment with glucocorticoids (OR 2.07,
95% CI 1.13–3.79, p 0.018) and lower scores in the PCS
(OR 0.95, 95% CI 0.92–0.97, p < 0.001) and MCS (OR
0.95, 95% CI 0.93–0.98, p < 0.001) scales of the SF-36
questionnaire. In multivariate analysis, only PCS (ad-
justed odds ratio (adjOR) 0.96, 95% CI 0.93–0.98, p =
0.006) and MCS (adjOR 0.96, 95% CI 0.93–0.99, p =
0.003) were independently associated with positive dis-
cordance (Supplementary material).
When a discrepancy score ≥ + 1 was applied to identify
positive discordance, a significant association in univari-
ate analysis was found for active mucocutaneous lesions
(OR 1.99, 95% CI 1.15–3.44, p = 0.014), ongoing treat-
ment with glucocorticoid (OR 2.00, 95% CI 1.17–3.40,
p = 0.011), and lower values of the PCS (OR 0.95, 95%
CI 0.93–0.98, p < 0.001) and MCS (OR 0.94, 95% CI
0.92–0.96, p < 0.001). In multivariate analysis, an inde-
pendent association was confirmed only for PCS (adjOR
0.97, 95% CI 0.92–1.00, p = 0.046) and MCS (adjOR
0.95, 95% CI 0.92–0.98, p < 0.001) (Supplementary
material).
Determinants of negative discordance (PtGA<PGA)
In univariate analysis, negative discordance, as defined
by a discrepancy score ≤ − 2, was significantly associated
with active ocular involvement (OR 6.93, 95% CI 1.24–
38.78, p = 0.027), whereas a trend toward statistical sig-
nificance was found for the association with the presence
of any chronic comorbidity (OR 4.03, 95% CI 0.80–
20.43, p = 0.092). In multivariable analysis, active ocular
lesions were confirmed to be the only factor independ-
ently associated with negative discordance (adjOR 7.68,
95% CI 1.29–45.59, p = 0.025) (Supplementary material).
When a discrepancy score ≤ − 1 was applied to identify
negative discordance, a significant association in univari-
ate analysis was found for active ocular involvement (OR
4.85, 95% CI 1.34–17.54, p = 0.016), whereas a trend toward
statistical significance was found for the presence of any
chronic comorbidity (OR 2.34, 95% CI 0.98–5.60, p = 0.056)
and not-use of biologic drugs (OR 0.14, 95% CI 0.02–1.06,
p = 0.057). In multivariable analysis, active ocular lesions
were confirmed to be the only factor independently
Table 1 Baseline features of the study cohort (n = 226)
Males, n (%) 111 (49.1%)
Age at enrolment, median (IQR) years 46.9 (35.6–55.2)
Disease duration, median (IQR) years 11.7 (5.9–20.8)
Comorbidities, n (%) 99 (43.8%)
Active disease manifestations
Mucocutaneous lesions, n (%) 83 (36.7%)
Ocular involvement, n (%) 12 (5.3%)
Arthritis, n (%) 17 (7.5%)
Major organ involvement, n (%) 20 (8.8%)
Disease activity indices
PGA, median (IQR) score 1.0 (0.0–3.0)
PtGA, median (IQR) score 2.0 (0.3–5.0)
BDCAF, median (IQR) score 3.0 (0.0–5.0)
Irreversible organ damage
BODI, median (IQR) score 1.0 (0.0–2.0)
HR-QoL (by SF-26)
PCS, median (IQR) score 46.6 (38.8–54.2)
MCS, median (IQR) score 44.9 (35.9–54.4)
Current and past therapy
Colchicine, n (%) 107 (47.3%)
Glucocorticoids, n (%) 104 (45.6%)
Immunosuppressants, n (%) 95 (42.0%)
Biologics, n (%) 49 (21.7%)
IQR interquartile range, BDCAF Behçet’s Disease Current Activity Form, PGA
physician global assessment, PtGA patient global assessment of disease
activity, BODI Behçet’s syndrome Overall Damage Index, HR-QoL health-related
quality of life, PCS physical component summary in the SF-36 questionnaire,
MCS mental component summary in the SF-36 questionnaire
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Fig. 2 Frequency of positive and negative discordance and concordance in the patients’ (PtGA) and physicians’ global assessment (PGA) of
disease activity, by using a PtGA-PGA discrepancy score of ± 2 (a) and ± 1 (b) as a threshold for significant discordance
Fig. 3 Changes in the prevalence of the PtGA-PGA discordance according to the different levels of disease activity, as assessed by the BDCAF. a
A cutoff of ± 1 was applied; b ± 2. PtGA, patient’s global assessment; PGA, physician’s global assessment; BDCAF, Behçet’s Disease Current
Activity Form
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associated with negative discordance (adjOR 5.88, 95% CI
1.48–23.30, p = 0.012) (Supplementary material).
Discussion
This study provides original and meaningful data on the
frequency, extent, and potential determinants of the gap
between patient’s and physician’s assessment of disease
activity in BS.
In our multicenter cohort, PtGA was on average
higher than PGA and the prevalence of discordance var-
ied (from 29.6 to 55.3%) according to the cutoff applied
for its definition. In case of disagreement, most patients
rated higher disease activity than their physicians (>
80%), whereas negative discordance was rare. Further,
discordance was more frequent in patients with high dis-
ease activity, according to the BDCAF. The patient-
perceived physical and mental domains of QoL played a
major role in the occurrence of positive PtGA-PGA dis-
cordance. Ocular involvement emerged as a potential
determinant of negative discordance, even though the
reliability of such result may be affected by the low of
prevalence of this type of discordance and the small
number of cases with active eye involvement.
The data on prevalence of PtGA-PGA discordance we
recorded in our BS cohort are consistent with those re-
ported in several other studies on different rheumatic
diseases, where a trend toward a higher rating of disease
activity by patients than by their physicians was observed
in 30–50% of cases. In many of these studies, the au-
thors concluded that using PtGA without an adequate
counterbalance by other objective indices may result in
overtreatment of patients because of non-inflammatory
alterations that are unresponsive to the pharmacological
therapy [7–11]. In our cohort, we observed a high fre-
quency of agreement between PtGA and PGA in pa-
tients with low BDCAF values, whereas the level of
disagreement grew up as the BDCAF values increased.
These findings suggest that patients and physicians have
a higher level of agreement in judging inactive disease
state, whereas they mainly disagree in judging the extent
and severity of active manifestations. Moreover, evidence
of the self-perceived physical and mental domains of
QoL as main determinant of discordance would reveal
that, when patients are asked to evaluate how much
their BS is active, they might be influenced by other as-
pects of their health and well-being. From a clinical
point of view, the agreement between PtGA and PGA in
scoring low levels of disease activity ensures a high prob-
ability of correctly classifying the low BS activity state.
This could be of special interest for the future definition
of core set domains for low disease activity or disease re-
mission. On the other hand, disagreement in judging the
extent of disease activity should induce clinicians to an
in-depth assessment aimed to identify the reasons for
discordance and exclude incipient or unapparent disease
manifestations. Further longitudinal studies are needed
to understand how considering the PtGA-PGA disagree-
ment in the therapeutic decision-making.
Some limitations should be taken into account inter-
preting the results of our study. First, the small number
of patients from other countries with high prevalence of
BS may limit the generalizability of our findings. Second,
education and socio-economic factors were not included
as potential determinants of discordance, because of the
lack of these data in the BODI study. Finally, the low fre-
quency of active major organ involvement in our cohort
may have prevented to identify its role in explaining the
occurrence of PtGA-PGA discordance.
Conclusions
Patient-assessed and physician-assessed measures of dis-
ease activity should be considered as complementary
and should be used together to improve the mutual un-
derstanding of disease activity state, as well as the part-
nership in the disease management. Particularly, PtGA
may be a useful tool in the assessment of BS disease ac-
tivity, as it carries a low risk to misclassify an inactive
disease, and may allow to capture aspects of the patients
health that negatively affect their well-being and the
treatment outcomes. Further research is needed to
evaluate the long-term consequence of discordance and
the benefit of specific interventions for its reduction.
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